Seven analysts set USD 554.60 target for Chemed stock

Published on 10/17/2026 at 22:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Chemed reports third-quarter results on October 27, 2026. Chemed stock closed at USD 512.38 on October 16, 2026, down 0.59 percent versus the NYSE prior close.

Analyst view and schedule

Seven firms gave Chemed an average USD 554.60 target on October 13, 2026.
Chemed announced third-quarter results for October 27, 2026.
Chemed stock closed at USD 512.38 on October 16, 2026, down 0.59 percent versus the NYSE prior close.
Chemed had a P/E ratio of 25.72 and a market capitalization of USD 6.7 billion on October 16, 2026.

CHE, US16359R1032, Illustration mit AI erstellt.

Seven research firms gave Chemed Corporation (ISIN US16359R1032) an average 12-month target of USD 554.60 on October 13, 2026, placing the target 8.24 percent above the stock's USD 512.38 closing price. MarketBeat said five firms rated the stock Hold and two rated it Buy. Chemed stock closed at USD 512.38 on the New York Stock Exchange on October 16, 2026, at 4:00 p.m. EDT, down 0.59 percent versus the NYSE prior close.

Earnings date sets the next test

Chemed announced on October 1, 2026 that it will release third-quarter results after the NYSE close on October 27, 2026. The company will discuss those results during a conference call on October 28, 2026, at 10:00 a.m. ET, according to GlobeNewswire. The scheduled release gives the analyst target a near-term test.

Range leaves room below the high

The October 16 closing price stood 8.01 percent below Chemed's 52-week high of USD 557.00 and 40.29 percent above its low of USD 365.21. The stock's year-to-date gain was 20.23 percent as of October 16, 2026. Trading volume was 89,398 shares, compared with an average volume of 157,240 shares.

Valuation stays measurable

Chemed's market capitalization was USD 6.7 billion and its trailing P/E ratio was 25.72 on October 16, 2026. The annualized dividend yield was 0.60 percent on October 13, 2026. In the second quarter of 2026, revenue reached USD 673.25 million, up 8.80 percent from the year-earlier quarter, while net income attributable to common shareholders was USD 67.70 million and diluted earnings per share were USD 5.13.

Comparison with peers

Chemed (NYSE, USD): minus 0.59 percent, P/E 25.72, market capitalization USD 6.7 billion
Encompass Health (NYSE, USD): plus 0.08 percent, P/E 20.83, market capitalization USD 12.6 billion
Addus HomeCare (NYSE, USD): minus 0.44 percent, P/E 20.35, market capitalization USD 2.2 billion

A dated market frame

Chemed operates VITAS Healthcare and Roto-Rooter, giving the company exposure to hospice care and plumbing services. The October 27 results date, the USD 554.60 analyst average and the 8.01 percent gap to the 52-week high define the next observable checkpoints for the stock.